SOX2 regulates paclitaxel resistance of A549 non-small cell lung cancer cells via promoting transcription of ClC-3

Paclitaxel (PTX) is widely used in the treatment of non-small cell lung cancer (NSCLC). However, acquired PTX drug resistance is a major obstacle to its therapeutic efficacy and the underlying mechanisms are still unclear. The present study revealed a novel role of the SRY-box transcription factor 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Youwei, Wang, Xiangyu, Hu, Rendong, Pan, Guopeng, Lin, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478990/
https://www.ncbi.nlm.nih.gov/pubmed/36069232
http://dx.doi.org/10.3892/or.2022.8396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478990/
https://www.ncbi.nlm.nih.gov/pubmed/36069232
http://dx.doi.org/10.3892/or.2022.8396

Ejemplares similares